-

Axion BioSystems Introduces New High-Throughput, Multiplate Maestro TrayZ Platform

ATLANTA--(BUSINESS WIRE)--Axion BioSystems today announces Maestro TrayZ, an innovative, live-cell analysis platform designed for high-throughput drug development and therapeutic discovery. The new system—featuring a slim multiplate tray design that allows for modular scalability and fits comfortably inside an incubator—joins Axion’s growing suite of next-generation Maestro products and offers a flexible, affordable option for noninvasive, label-free monitoring of live cells in real time.

“The paradigm-shifting Maestro TrayZ platform meets growing customer demand for a high-throughput, cost-effective tool that can help bring novel cell-based treatments to the market faster,” stated Kevin Gould, Axion BioSystems’ CEO. “I applaud Axion’s remarkable product development team for this achievement and expect the new system will quickly become indispensable for scientists and drug developers.”

According to Axion’s President and CTO Jim Ross, the scalable tray design is a gamechanger for users. “The Maestro TrayZ platform provides a great deal of flexibility, allowing users to add trays to increase the throughput to meet their needs and easily run multiple experiments in a controlled, GMP-compatible environment. This high-throughput capacity, combined with Axion’s signature intuitive controls, powerful software, and automated tracking keeps the increased throughput from increasing the workload, making the system a great fit for any discovery and manufacturing workflow.”

Today’s complex cell-based therapeutics, such as CAR T cell therapies for immuno-oncology applications, demand powerful in vitro assays that can accurately characterize cellular interactions during preclinical development and ensure product consistency throughout the manufacturing process. While conventional assays are limited to a single snapshot in time and can miss important markers of cellular activity, Axion BioSystems’ label-free, noninvasive Maestro TrayZ—which uses sensitive bioelectrodes to continuously monitor the potency of immune cell-mediated killing—enables scientists to efficiently test new therapeutic candidates and maintain the quality of cell-based products in real time. Designed with a regulatory environment in mind, Maestro TrayZ boasts GMP-compliance software, barcode plate tracking, environmental monitoring, and automated event logging.

“Since the launch of the original Maestro Z in 2020, we have been gratified to see how scientists around the world are using our systems to accelerate the development of urgently needed immunotherapies, identify potential antivirals, and investigate other complex cellular behavior in vitro,” added CEO Kevin Gould. “The Maestro TrayZ takes it to the next level, and we look forward to seeing how users will continue to break new ground.”

About Axion BioSystems

Axion BioSystems is a leading life sciences tools company focused on innovative live-cell assays used to study the function of cells in vitro for drug discovery and disease modeling. The team at Axion BioSystems is dedicated to continuing the advancement of new technologies that accelerate research and further the understanding of biological complexity outside of the body. Axion BioSystems is headquartered in Atlanta, Georgia, USA, and has offices worldwide. Axion has more than 150 employees across its current locations. www.axionbiosystems.com

Contacts

Mike Clements
Vice President Marketing, Axion BioSystems
+1-678-469-3439
mclements@axionbio.com

Axion BioSystems


Release Summary
Axion BioSystems introduces the new multiplate Maestro TrayZ platform, designed for high-throughput drug development and therapeutic discovery.
Release Versions

Contacts

Mike Clements
Vice President Marketing, Axion BioSystems
+1-678-469-3439
mclements@axionbio.com

Social Media Profiles
More News From Axion BioSystems

Harnessing Combined Expertise: STEMCELL Technologies and Axion BioSystems Partner to Streamline Culture and Analysis of Excitable Cells

ATLANTA & VANCOUVER, British Columbia--(BUSINESS WIRE)--Axion BioSystems and STEMCELL Technologies are pleased to announce a strategic partnership that will enable STEMCELL to sell Axion’s state-of-the-art Maestro Pro™ and Maestro Edge™ multielectrode array (MEA) systems within North America and Europe. The industry-leading Maestro MEA systems will also continue to be available for purchase worldwide directly from Axion BioSystems. Through this partnership, Axion and STEMCELL will enable scient...

Axion BioSystems Continues Agreement Giving Corning® Exclusive Rights to Distribute Award-Winning Cell Counting Device

ATLANTA--(BUSINESS WIRE)--Axion BioSystems today announced an agreement with Corning Incorporated (NYSE: GLW) that continues Corning’s exclusive worldwide distribution rights for the Corning® Cell Counter. The simple yet powerful device, developed by Axion BioSystems and distributed by Corning, was recently included in the SelectScience® top 10 list of remarkable products advancing life science research. The agreement extends the successful collaboration between Corning and Axion BioSystems to...

Axion BioSystems Adds Affordable Maestro Volt™ to its Industry-Leading MEA System Lineup

ATLANTA--(BUSINESS WIRE)--Axion BioSystems today announced the launch of the new Maestro Volt™, an affordable benchtop microelectrode array (MEA) system designed to meet the demands of academic labs with lower throughput needs and limited budgets. Featuring the same ease of use, high-quality controls, and intuitive software synonymous with the Maestro name, the 6-well Maestro Volt is available for both neurological and cardiovascular research applications. The new device expands Axion’s flagshi...
Back to Newsroom